JP2024530166A5 - - Google Patents
Info
- Publication number
- JP2024530166A5 JP2024530166A5 JP2024506663A JP2024506663A JP2024530166A5 JP 2024530166 A5 JP2024530166 A5 JP 2024530166A5 JP 2024506663 A JP2024506663 A JP 2024506663A JP 2024506663 A JP2024506663 A JP 2024506663A JP 2024530166 A5 JP2024530166 A5 JP 2024530166A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- cancer
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163229125P | 2021-08-04 | 2021-08-04 | |
| US63/229,125 | 2021-08-04 | ||
| PCT/US2022/039301 WO2023014809A2 (en) | 2021-08-04 | 2022-08-03 | Cd3 targeting antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024530166A JP2024530166A (ja) | 2024-08-16 |
| JP2024530166A5 true JP2024530166A5 (https=) | 2025-08-13 |
Family
ID=85156302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024506663A Pending JP2024530166A (ja) | 2021-08-04 | 2022-08-03 | Ｃｄ３標的化抗体及びそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250340637A1 (https=) |
| EP (1) | EP4380631A4 (https=) |
| JP (1) | JP2024530166A (https=) |
| KR (1) | KR20240040097A (https=) |
| CN (1) | CN118043357A (https=) |
| AU (1) | AU2022323246A1 (https=) |
| CA (1) | CA3228257A1 (https=) |
| WO (1) | WO2023014809A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023010541A (es) | 2021-03-09 | 2023-11-24 | Cdr Life Ag | Proteinas de union al antigeno del peptido del mhc mage-a4. |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| CA3264474A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT |
| CN116574182B (zh) * | 2023-06-09 | 2024-02-06 | 上海交通大学医学院附属第九人民医院 | 一种抗人Ki-67抗体及其制备方法和用途 |
| CN118027196B (zh) * | 2023-06-25 | 2025-12-02 | 合肥天港免疫药物有限公司 | 抗cd3抗体及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016538275A (ja) * | 2013-11-04 | 2016-12-08 | グレンマーク ファーマシューティカルズ， エセ．アー． | Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造 |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| CN118894936A (zh) * | 2017-05-08 | 2024-11-05 | 阿迪马布有限责任公司 | 抗cd3结合结构域和包含它们的抗体以及它们的产生及使用方法 |
| WO2019034580A1 (en) * | 2017-08-14 | 2019-02-21 | Morphosys Ag | HUMANIZED ANTIBODIES FOR CD3 |
| CN110305217B (zh) * | 2018-03-27 | 2022-03-29 | 广州爱思迈生物医药科技有限公司 | 双特异性抗体及其应用 |
| KR102239781B1 (ko) * | 2019-04-08 | 2021-04-13 | 주식회사 녹십자 | Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 |
-
2022
- 2022-08-03 EP EP22853863.3A patent/EP4380631A4/en active Pending
- 2022-08-03 US US18/294,755 patent/US20250340637A1/en active Pending
- 2022-08-03 CN CN202280066037.7A patent/CN118043357A/zh active Pending
- 2022-08-03 AU AU2022323246A patent/AU2022323246A1/en active Pending
- 2022-08-03 KR KR1020247006244A patent/KR20240040097A/ko active Pending
- 2022-08-03 CA CA3228257A patent/CA3228257A1/en active Pending
- 2022-08-03 WO PCT/US2022/039301 patent/WO2023014809A2/en not_active Ceased
- 2022-08-03 JP JP2024506663A patent/JP2024530166A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024530166A5 (https=) | ||
| JP2023523584A5 (https=) | ||
| Runcie et al. | Bi-specific and tri-specific antibodies-the next big thing in solid tumor therapeutics | |
| Paul et al. | Cancer therapy with antibodies | |
| JP2023537002A5 (https=) | ||
| JP2022546572A5 (https=) | ||
| Friedman et al. | Engineered affinity proteins for tumour‐targeting applications | |
| Thakur et al. | Cancer therapy with bispecific antibodies: Clinical experience | |
| Cao et al. | Bispecific antibodies as novel bioconjugates | |
| JP2022525435A5 (https=) | ||
| JP2020523029A5 (https=) | ||
| Nielsen et al. | Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries | |
| JP2022538117A5 (https=) | ||
| IL273484B1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
| Chester et al. | Engineering antibodies for clinical applications in cancer | |
| JP2021503927A5 (https=) | ||
| RU2017145150A (ru) | Антитело против pdl-1, его фармацевтическая композиция и применение | |
| WO2022216965A1 (en) | Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells | |
| JP2020534017A5 (https=) | ||
| Dorvillius et al. | Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen | |
| Guo et al. | Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment | |
| Lin et al. | The evolution of antibodies into versatile tumor-targeting agents | |
| WO2019052508A1 (zh) | 放射性标记抗纳米抗体在癌症的预后、诊断中的应用 | |
| Sirk et al. | Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2 | |
| JP2021517816A5 (https=) |